Business
SOPHiA GENETICS Announces Expanded Suite of Liquid Biopsy Offerings
World-class liquid biopsy testing will be available to SOPHiA GENETICS customers BOSTON and ROLLE, Switzerland, Dec. 7, 2023 /PRNewswire/ -- SOPHiA GENETICS
About this update from Sophia Genetics Sa
[{"type":"text","content":"World-class liquid biopsy testing will be available to SOPHiA GENETICS customers \nBOSTON and ROLLE, Switzerland, Dec. 7, 2023 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced an expanded suite of solutions under SOPHiA DDM™ for Liquid Biopsy. The range of solutions, including MSK-ACCESS® powered with SOPHiA DDM™ and custom solutions, will help progress oncology research and tumor mutation profiling. The rollout of SOPHiA GENETICS' liquid biopsy capabilities demonstrates the company's commitment to developing advanced solutions that empower timely, critical decision-making and improve health outcomes.\n\n \n \n \n \n \n \n\n \nFor a sizeable number of cases, genomic testing of tumor tissue is not feasible due to either insufficient tissue material, low quality of the obtained tissue, or the invasiveness of the procedure. Liquid biopsy testing offers an alternative to solid tumor testing by isolating cell-free DNA (cfDNA) from blood plasma, which may uncover circulating tumor DNA (ctDNA). Isolating these DNA samples from a simple blood draw can help guide clinical decisions in a manner that is faster and less invasive, expedite results for researchers and clinicians, and simplify monitoring. SOPHiA GENETICS' liquid biopsy offering will help users enhance tumor profiling with advanced cfDNA analysis and a streamlined DNA-only NGS workflow, allowing users to go from extracted cfDNA to comprehensive report in an efficient timeframe. SOPHiA DDM™ for Liquid Biopsy features SOPHiA GENETICS' proprietary unique molecular identifier technology (CUMIN™) that is designed to transform the way labs analyze cell-free DNA samples with exceptional performance and reliable results.\n\"Our goal at SOPHiA GENETICS is to increase the use of data-driven medicine around the world and decrease health inequities by making resources more accessible to all,\" said Philippe Menu, MD, PhD., Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS. \"Liquid biopsy is a sophisticated testing capability that can help expedite clinical decisions and planning. It is inherently cheaper and faster than traditional biopsy methods and is an excellent tool for labs and health systems to have at their disposal. We feel strongly that increased use of liquid biopsy will help adv...